Clinical trials: HER2 Gene Mutation
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study
The goal of this observational study is to examine whether markers of PI3K pathway activation are associated with endocrine therapy response and clinicopathologic features in estrogen receptor-positive, HER2-negative breast…
- Trial name
- p-AKT p-S6 (NCT07387861)
- Testing
- Not applicable- observational study
- Volunteers
- 70 people
- Sponsor
- Assiut University
HER2 Gene Mutation, Adenocarcinoma Lung Stage IV
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
In this trial, treatment efficacy and safety of Poziotinib will be assessed in patients with stage IV lung adenocarcinoma harboring HER2 mutation.
- Trial name
- NCT02979821
- Testing
- Poziotinib
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Korean Association for the Study of Targeted Therapy